<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129713</url>
  </required_header>
  <id_info>
    <org_study_id>NEXIUM versus SECRETOL</org_study_id>
    <nct_id>NCT01129713</nct_id>
  </id_info>
  <brief_title>Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.</brief_title>
  <official_title>Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effexus Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Arizona VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Effexus Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with
      Secretol 80/80 versus Nexium 40 mg daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that Secretol 80/80 daily will demonstrate better efficacy than Nexium 40 mg
      daily in healing erosive esophagitis(EE)and controlling gastroesophageal reflux
      disease(GERD)related symptoms after 3 weeks of treatment.In addition, Secretol 80/80 daily
      will have a faster effect on the aforementioned clinical parameters but a similar safety
      profile.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective is to evaluate the relationship between healing and study drug allotment.</measure>
    <time_frame>3 weeks of treatment</time_frame>
    <description>The primary objective is to evaluate the relationship between healing and study drug allotment. The variables to be used are erosive esophagitis healing status after 3 weeks of treatment as assessed by EGD (upper endoscopy) comparing to base line EGD.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <condition>Heartburn</condition>
  <condition>Indigestion</condition>
  <arm_group>
    <arm_group_label>Nexium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparing 40 mg.once daily in healing erosive esophagitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secretol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secretol</intervention_name>
    <description>Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.</description>
    <arm_group_label>Secretol</arm_group_label>
    <other_name>lansoprazole/omeprazole combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.</description>
    <arm_group_label>Nexium</arm_group_label>
    <other_name>Esomeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Ages 18-75

          -  EE Los Angeles grades C or D

          -  Heartburn and/or regurgitation at least 3 times a week during the 7 day run- in period
             prior to randomization.

          -  Able to read, understand, and complete study questionnaires and record

          -  Able to understand the study procedures and sign informed consent

          -  Able to comply with all study requirements

        Exclusion Criteria:

          -  Subjects with Barrett's esophagus, non-erosive reflux disease,EE grades A or B, or
             peptic stricture on endoscopy

          -  Subjects with previous upper gastrointestinal surgery

          -  Subjects with clinically significant underlying comorbidity

          -  Helicobacter pylori positive

          -  Clinically significant GI bleed within the last 3 months

          -  Esophagitis not related to acid reflux

          -  Bleeding disorder

          -  Zollinger-Ellison, achalasia,esophageal varices, duodenal/gastric ulcer, upper
             gastrointestinal malignancy

          -  Women pregnant or lactating

          -  History of allergic reaction to any Proton Pump Inhibitor (PPI)

          -  Patients can't be treated concurrently with warfarin or other
             anticoagulants,salicylates,steroids,NSAIDS &gt; 3 times/week

          -  Any medication dependant on gastric acid for optimal absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronnie Fass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Arizona VA Health Care System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronnie Fass, MD</last_name>
    <phone>520-792-1450</phone>
    <phone_ext>5139</phone_ext>
    <email>ronnie.fass@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcia R. Willis, BS,CCRC</last_name>
    <phone>520-792-1450</phone>
    <phone_ext>2032</phone_ext>
    <email>marcia.willis@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern Arizona Veterans Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronnie Fass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>Acid Reflux</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Regurgitation</keyword>
  <keyword>Indigestion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

